| Document |
Document Title |
|
WO/2024/080361A1 |
The present invention relates to a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. The compound of the invention has excellent α1A adrenergic receptor agonist activity and is useful as a proph...
|
|
WO/2024/079360A1 |
The present invention relates to a composition or combined preparation which comprises L-carnitine and essential oils, specially essential oils from savory (Satureja hortensis), parsley (Petroselinum crispum) and /or rosemary (Rosmarinus...
|
|
WO/2024/080952A1 |
The present invention relates to usage of hydrogen peroxide compounds as active substance in elimination of diabetic retinopathy diseases and the symptoms resulting from these diseases, and pharmaceutical compositions comprising hydrogen...
|
|
WO/2024/080441A1 |
The present invention provides: a Paracoccus aminovorans BM109 strain (accession number KCTC 15059BP), which is excellent for removing trimethylamine (TMA) or trimethylamine N-oxide (TMAO); and a pharmaceutical composition for preventing...
|
|
WO/2024/080377A1 |
The present invention pertains to a method for detecting pulmonary hypertension, the method comprising step (I-1) and step (I-2), in that order. In step (I-1), the content of myosin light chain 9 (Myl9) protein in a biological sample der...
|
|
WO/2024/080931A1 |
The present disclosure describes anti-inflammatory properties of red blood cell extracellular vesicles, e.g., as mediated by heme, hemoglobin and/or phosphatidylserine content. The present disclosure describes technologies useful for the...
|
|
WO/2024/081611A1 |
Methods for treating heart failure are described herein. The treatment methods include administering a cardiac sarcomere activator (e.g., omecamtiv mecarbil, or a pharmaceutically acceptable salt and/or hydrate thereof) to a subject in n...
|
|
WO/2024/080356A1 |
[Problem] To provide a drug effective for the treatment of an intractable lymphatic disease and an intractable vascular disease. [Solution] Provided is a therapeutic agent for an intractable lymphatic disease and an intractable vascular ...
|
|
WO/2024/035884A8 |
Disclosed herein are kits and methods for treating pulmonary arterial hypertension (PAH), comprising administering to a subject in need thereof: • a therapeutically effective amount of a tyrosine kinase inhibitor or a pharmaceutically ...
|
|
WO/2024/078488A1 |
Disclosed in the present invention are a thiochroman derivative and a preparation method therefor and a use thereof. The structure of the thiochroman derivative is as shown in general formula (I), and the definition of each substituent i...
|
|
WO/2024/044542A3 |
Described are methods for treating diseases and disorders that can be mediated in part by a reduction in ANGPTL3 gene expression in a human subject in need of treatment, using pharmaceutical compositions that include ANGPTL3 RNAi agents....
|
|
WO/2024/080323A1 |
Provided is a novel use of a composition that contains a prescribed sulfur-containing compound, a salt thereof, or both. The present invention is a sirtuin activator or expression enhancer, a NAD+ increasing agent, or a senescent cell in...
|
|
WO/2024/079324A1 |
The present invention relates to a composition for use in the treatment of a disease or disorder, wherein said disease or disorder is preferably a disease or disorder in which aldosterone overexposure contributes to the symptoms of said ...
|
|
WO/2024/081245A1 |
The present disclosure relates generally to methods of treating or preventing myocardial injury, or a condition associated with myocardial injury, in a mammal, wherein the method comprises administering at least one tissue differentiatio...
|
|
WO/2024/081925A1 |
Provided herein are lipid nanoparticle complex with nanoparticles cloaked in monocyte plasma membrane for effective delivery of drugs. Also provided herein are drug loaded lipid nanoparticle complex for inhibition of YAP/TAZ pathway and ...
|
|
WO/2024/078620A1 |
A nitrogen-containing heterocyclic derivative inhibitor, a preparation method therefor and the use thereof. Specifically disclosed are a compound as represented by general formula (I), a preparation method therefor, a pharmaceutical comp...
|
|
WO/2024/078124A1 |
Provided in the present invention is the use of a TDGF1 gene in the preparation of a drug for treating aging-related diseases or reversing cell aging. Compared with the prior art, the present invention has the following advantages: the u...
|
|
WO/2024/079603A1 |
The present invention relates to novel pharmaceutical formulations given by the association of an inhibitor of histone methyltransferase activity and chemotherapeutic drugs for use in the treatment of cancer, in particular of colon cance...
|
|
WO/2024/081928A1 |
The present invention relates to a hemoglobin protein composition comprising biologically active hemoglobin and less than 2% methemoglobin (metHb) wherein the metHb is maintained below 2% after reoxygenation of hemoglobin. Furthermore, h...
|
|
WO/2024/080661A1 |
The present invention relates to vMSC, which is a stem cell that is newly identified and has angiogenic properties. vMSCs cultured under specific culture conditions and identified, according to the present invention, are novel MSCs that ...
|
|
WO/2024/074116A1 |
The present invention relates to use of a compound represented by formula (I) or an ester thereof or a pharmaceutically acceptable salt thereof in the treatment of a disease accompanied by fibrosis.
|
|
WO/2024/075145A1 |
The present invention relates to a human dental pulp-derived stem cell population and culture supernatant thereof, a pharmaceutical composition comprising the stem cell population, and method for producing same. Specifically, the present...
|
|
WO/2024/075676A1 |
The present invention pertains to an agent that is for treating or preventing cerebral palsy, that contains dental pulp stem cells, and that is to be administered to a subject having a symptom of cerebral palsy.
|
|
WO/2024/075891A1 |
The present invention relates to a nitric oxide donor transporter (NODT) possessing low molecular weight levan. More specifically, a nitric oxide donor transporter composition includes low molecular weight levan with a molecular weight (...
|
|
WO/2024/075662A1 |
One purpose of the present disclosure is to provide a method for testing for the presence/absence of a stroke. The method for testing for the presence/absence of a stroke includes a step of measuring the presence/absence of at least on...
|
|
WO/2024/075139A1 |
The present application relates to an improved process for the preparation of finerenone and intermediates thereof, which is represented by the following structural formula-I.
|
|
WO/2024/074705A1 |
The present invention relates to a method of enhancing gene therapy by using an enzyme effective to degrade or digest and/or inhibit or reduce effector function of serum antibodies in the subject. More particularly, the subject is one th...
|
|
WO/2024/075815A1 |
The present invention addresses the problem of providing a cMLCK activator which can enhance myocardial contraction without the need to increase the concentration of calcium in cells. The problem is solved by a cMLCK activator comprising...
|
|
WO/2024/075017A1 |
The present invention relates to compounds useful for inhibiting calcification of aortic valves and to the treatment of diseases including aortic sclerosis and stenosis, and in particular to the use of the proton pump inhibitors includin...
|
|
WO/2024/076657A1 |
3 β-hydroxy-5-cholestenoic acid 3-sulfate (CA3S), a sulfated derivative of 3β-hydroxy-5-cholestenoic acid (CA), is provided. Both CA and CA3S have potent cholesterol and triglyceride lowering and anti-inflammatory activities. Methods o...
|
|
WO/2024/077310A1 |
A preparation comprising the YEL002 compound as an active ingredient for the prevention or treatment of one or more diseases or conditions, and methods of using such preparations. The preparations may be a sublingual pill, an injection, ...
|
|
WO/2024/075675A1 |
The present invention relates to: a stem cell population derived from human milk tooth dental pulp, the stem cell population being characterized in that at least 90% of the stem cell population is CD117-negative, CD73-positive, CD90-posi...
|
|
WO/2024/067531A1 |
Provided is a dual-targeting compound against FAP and integrin αvβ3. The targeting compound and a radionuclide marker thereof can synergistically target a FAP target and an integrin αvβ3 target in tumors, such that the number of and ...
|
|
WO/2024/071039A1 |
The present disclosure provides a pharmaceutical composition for treating or preventing T cell-related disorders, the pharmaceutical composition containing induced regulatory T cells having high functionality and a stable immunosuppressi...
|
|
WO/2024/067817A1 |
Provided is use of a neuregulin or a functional fragment thereof, or a nucleic acid encoding a neuregulin or a functional fragment thereof, or a substance for improving the yield and/or function of a neuregulin in a human body in the pre...
|
|
WO/2024/068976A1 |
The present invention relates to new compounds capable of inhibiting the activity of SHP2 phosphatase. Compounds of the invention can be used for the treatment of disorders associated with SHP2 deregulation. The present invention also re...
|
|
WO/2024/068153A1 |
This application relates generally to the field of treatment or prevention of "open" vascular surgical interventions with administration of a macrocyclic triene immunosuppressive compound in order to reduce or eliminate stenotic and/or v...
|
|
WO/2024/071223A1 |
The present invention provides a method for producing an angiogenesis-inducing cell population. This method comprises: (1) a step for coculturing a cell population derived from bone marrow fluid or blood with OP9 cells; or (2) a step for...
|
|
WO/2024/072793A1 |
The invention provides pyridine carboxamide compounds, pharmaceutical compositions, and their use in treating medical conditions.
|
|
WO/2024/067560A1 |
Disclosed in the present invention are a sulfonamide compound and the medical use thereof as a STING inhibitor, specifically, a compound as represented by formula (I) or a pharmaceutically acceptable salt or ester or solvate thereof, whi...
|
|
WO/2024/071480A2 |
The present invention relates to a pharmaceutical composition containing gold nanoparticles as an active ingredient for the treatment or prevention of thrombotic diseases. In the present invention, the gold nanoparticle forms a complex w...
|
|
WO/2024/067691A1 |
Disclosed are a nitrogen-containing heterocyclic compound and pharmaceutical use thereof. Specifically, disclosed are a nitrogen-containing heterocyclic compound represented by general formula (I), a preparation method therefor, a pharma...
|
|
WO/2024/072794A1 |
The invention provides pyridine carboxamide compounds, pharmaceutical compositions, and their use in treating medical conditions.
|
|
WO/2024/072079A1 |
The present invention relates to a pharmaceutical composition for preventing or treating cardiovascular aging diseases, comprising enavogliflozin as an active ingredient. Enavogliflozin of the present invention exhibits excellent effects...
|
|
WO/2024/073426A1 |
Provided dihydroquinazolinone and azadihydroquinazolinone compounds for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction.
|
|
WO/2023/219376A9 |
The present invention relates to: a natural composition for inhibiting the production of carcinogenic N-nitrosamine in the stomach and intestines and promoting the production of nitric oxide in the intestines; and a use thereof. The natu...
|
|
WO/2024/067845A1 |
An imidazopyridine compound represented by formula (I) as an IRAK4 degradation agent, a tautomer thereof, a stereoisomer thereof, a hydrate thereof, a solvate thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The...
|
|
WO/2024/063537A1 |
The pharmaceutical composition containing the sacubitrilㆍvalsartan calcium salt of the present invention comprises colloidal silicon dioxide and optionally further comprises inorganic magnesium salt to have excellent dissolution rate a...
|
|
WO/2024/062360A1 |
A compound of formula (I) having the structure: or a pharmaceutically acceptable salt thereof as SIK inhibitor, wherein A1 and A2 are independently O or S; X is selected from CH2, CD2, NR3, O, and S, where R3 is selected from hydrogen, C...
|
|
WO/2024/061097A1 |
Provided are an anti-platelet aggregation medicament and use thereof. The medicament is a compound having a structure of formula I, or a pharmaceutically acceptable salt thereof, a solvate thereof, or a deuterated substance thereof. The ...
|
